The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies

Adam J. Fein, Ph.D.
Pembroke Consulting, Inc., and Drug Channels Institute

January 2016

Copyright © 2016 by Pembroke Consulting, Inc. All rights reserved.

This report is protected by copyright law and may not be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed, or resold, in whole or in part, in any form or manner or by any means whatsoever, by any person without prior written consent. This report may be cited in commercial documents with full and appropriate attribution. This report is for informational purposes only and is provided “as is” without any express or implied warranty. The analyses in this report are based solely on information and data that are in the public domain. All conclusions, findings, opinions, and recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc., Drug Channels Institute, or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc., and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc., and Drug Channels Institute do not make investment recommendations in this report or otherwise. Nothing in this report should be interpreted as an opinion by Pembroke Consulting, Inc., Drug Channels Institute, or the author on the investment prospects of specific companies.

Drug Channels® is a registered trademark of Pembroke Consulting, Inc.
LICENSE TERMS

This report is protected by copyright law. Unauthorized reproduction or distribution of this report or any portion of it may result in severe civil and criminal penalties and will be prosecuted to the maximum extent of the law. This report may be cited in commercial documents with full and appropriate attribution. Nothing in the license is intended to reduce, limit, or restrict any rights arising from fair use under copyright law or other applicable laws.

There are four license term options for The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies:

- **Single User License:** This license allows for use of this report by one individual person. This person may use the report on any computer, and may print out the report, but may not share the report with any other person or persons. Unless a Department/Team or Corporate License is purchased, a Single User License must be purchased for every person who wishes to use the report within the same organization or enterprise. Buyers who infringe upon these license terms are liable for a Department/Team or Corporate License fee.

- **Department/Team License:** This license allows for use of this report by up to 10 (ten) employees within the same organization or enterprise as the purchaser identified in the upper left corner of this page. Each of these employees may use the report on any computer, and may print out the report, but may not share the report with any other person or persons unless a Corporate License is purchased. Buyers who infringe upon these license terms are liable for a Corporate License fee.

- **Corporate License:** This license allows for use of the report by an unlimited number of employees within the same organization or enterprise worldwide as the purchaser identified in the upper left corner of this page. Each of the employees within this organization or enterprise may use the report on any computer, and may print out the report, but may not share the report with any other person or persons outside the enterprise or organization.

- **Corporate License + Exhibits:** This license has the same terms as the Corporate License and includes a PowerPoint file with images of all exhibits in the report. These exhibits can be used under the same terms and conditions as the report can be used.

ABOUT THE AUTHOR

Adam J. Fein, Ph.D., is the president of Pembroke Consulting, Inc., a management advisory and business research firm based in Philadelphia. He also is the CEO of Pembroke’s Drug Channels Institute, a leading management educator for and about the pharmaceutical industry.

Dr. Fein is one of the country’s foremost experts on pharmaceutical economics and the drug distribution system. Top manufacturers call on Dr. Fein’s insights and judgment to create successful commercial strategies and make better strategic decisions in our evolving healthcare environment.

Dr. Fein’s popular and influential Drug Channels website (www.DrugChannels.net) is the go-to source for definitive and comprehensive industry analysis, delivered with a witty edge. He has published hundreds of academic and industry articles, and is regularly quoted in such national publications as The Wall Street Journal, The New York Times, USA Today, Pharmaceutical Executive, and many others. He serves on the editorial advisory boards of Pharmaceutical Commerce and Drug Benefit News.

Dr. Fein earned his Ph.D. from the Wharton School of Business at the University of Pennsylvania and a B.A., summa cum laude, from Brandeis University. He lives in Philadelphia with his wife, Paula, and their two children.

Contact information
Adam J. Fein, Ph.D.
Pembroke Consulting, Inc.
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700
Website: www.PembrokeConsulting.com
Email: afein@pembrokeconsulting.com

Visit the Drug Channels website for the latest industry updates!

www.DrugChannels.net
ABOUT DRUG CHANNELS INSTITUTE

Drug Channels Institute (DCI), a division of Pembroke Consulting, Inc., is a leading provider of specialized management education and computer-based training for and about the pharmaceutical industry.

Drug Channels Institute combines Dr. Fein’s expertise and cutting-edge analysis—such as The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies—into online e-learning modules that offer a thorough grounding in crucial industry topics, all in 45 minutes or less.

These online learning tools mix the latest industry data and cutting-edge analysis with highly interactive elements that engage and entertain. They educate a wide variety of learners: from sales reps and field teams—who need immediate, easily digestible industry concepts for their key accounts—to internal teams who need to better understand customers and channels.

View a module list at http://drugchannelsinstitute.com/products/e-learning-modules/.

View a sample at http://drugchannelsinstitute.com/e-learning-module-sample/.

DCI can code and brand any module for your company’s internal Learning Management System. Or you can get started quickly by letting us host your team via our online e-learning portal. DCI’s hosted e-learning modules are instantly viewable on all computer platforms, including iPads.

To learn more about how Drug Channels Institute can help your business, please contact:

Paula Fein, M.S.Ed.
V.P., Business Development
Drug Channels Institute
1515 Market Street, Suite 960
Philadelphia, PA 19102
Phone: 215-523-5700 x11
Website: www.drugchannelsinstitute.com
Email: paula@drugchannelsinstitute.com
INTRODUCTION AND GUIDE TO THIS REPORT

In 2015, amid significant growth, the $364 billion pharmacy industry began to transform its fundamental structure. Healthcare reform, for instance, is reshaping drug benefits but remains politically contentious. Specialty drugs and specialty pharmacies are booming, as the generic dispensing rate plateaus. Meanwhile, major mergers and acquisitions among pharmacies, health plans, and PBMs will leave the industry more consolidated than ever before. Given these and other changes, understanding the implications of the industry’s evolution is crucial.

The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies—our seventh edition—remains the most up-to-date, comprehensive, fact-based analysis of the pharmacy channel and its interactions with other participants in our healthcare system. I have synthesized a wealth of statistical data, research studies, financial information, and my own unique business consulting experience into a definitive, nonpartisan resource.

This report is your ultimate guide to the complex web of interactions within the pharmacy distribution and reimbursement system. It helps pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, benefit managers, managed care executives, healthcare policy analysts, investors, consultants—anyone who wants to understand and benefit from this ever-changing industry.

About the Report

Thousands of companies operate in the U.S. pharmacy distribution and reimbursement system, ultimately enabling more than five billion equivalent prescriptions to be dispensed and paid. The table below highlights the major public companies operating in the pharmacy distribution and reimbursement system. The 2016 edition of this report contains the latest financial and industry data about the strategies and market positions of the largest public companies: CVS Health, Express Scripts, Rite Aid, Walgreens Boots Alliance, OptumRx, Walmart, and others.

Major Public Companies Operating in Pharmacy Drug Channels

<table>
<thead>
<tr>
<th>Company</th>
<th>Stock Ticker</th>
<th>Primary U.S. Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS Health</td>
<td>CVS</td>
<td>Chain Drugstore/Pharmacy Benefit Manager</td>
</tr>
<tr>
<td>Diplomat Pharmacy</td>
<td>DPLO</td>
<td>Specialty Pharmacy</td>
</tr>
<tr>
<td>Rite Aid Corporation*</td>
<td>RAD</td>
<td>Chain Drugstore/Pharmacy Benefit Manager</td>
</tr>
<tr>
<td>Walgreens Boots Alliance</td>
<td>WBA</td>
<td>Chain Drugstore</td>
</tr>
<tr>
<td>Walmart Stores, Inc.</td>
<td>WMT</td>
<td>Mass merchant with pharmacy</td>
</tr>
<tr>
<td>AmerisourceBergen Corp.</td>
<td>ABC</td>
<td>Pharmaceutical Wholesaler</td>
</tr>
<tr>
<td>Cardinal Health, Inc.</td>
<td>CAH</td>
<td>Pharmaceutical Wholesaler</td>
</tr>
<tr>
<td>McKesson Corporation</td>
<td>MCK</td>
<td>Pharmaceutical Wholesaler</td>
</tr>
<tr>
<td>Express Scripts, Inc.</td>
<td>ESRX</td>
<td>Pharmacy Benefit Manager/Mail &amp; Specialty Pharmacy</td>
</tr>
<tr>
<td>OptumRx (UnitedHealth Group)</td>
<td>UNH</td>
<td>Pharmacy Benefit Manager/Mail &amp; Specialty Pharmacy</td>
</tr>
</tbody>
</table>

* In October 2015, Walgreens Boots Alliance announced its acquisition of Rite Aid. 
Source: Pembroke Consulting research
This complex system, illustrated below, contains three key channel flows that we discuss in *The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies*:

- **Product movement**, which traces bulk shipments from pharmaceutical manufacturers to the drug wholesalers that supply pharmacies. A pharmacy marks the final step in which a prescription is dispensed to a patient.

- **Financial flows**, which transfer money from third-party payers to Pharmacy Benefit Managers (PBMs), who in turn reimburse pharmacies. Funds flow to manufacturers via pharmacies, which purchase drugs from wholesalers. Funds flow from manufacturers in the form of rebates to PBMs, which share a portion of these payments with plan sponsors, reducing net prescription costs. Manufacturers’ rebates to PBMs and other third-party payers do not flow through wholesale or retail channels.

- **Contractual relationships**, which govern the relationships between: 1) payers and PBMs; 2) PBMs and pharmacies; 3) pharmacies and wholesalers; 4) wholesalers and manufacturers; and 5) manufacturers and PBMs.

---

Chart illustrates flows for Patient-Administered, Outpatient Brand-Name Drugs. Please note that this chart is illustrative. It is not intended to be a complete representation of every type of financial, product flow, or contractual relationship in the marketplace.

Source: Pembroke Consulting research
Structure of the 2016 Report

To better reflect the changing industry, this year’s edition has been completely updated, reorganized, and expanded. Therefore, the chapters and sections do not correspond to those of previous editions. The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies analyzes the industry in three major sections, comprising ten chapters. In addition to updating all market data and information, this 2016 edition includes many new elements. We have also integrated the trend and outlook material into the main chapters. This provides a more unified analysis of key industry issues.

Section I: The U.S. Pharmacy Industry

- **Chapter 1: Industry Overview** (page 2) defines the industry and its regulatory framework, explains different pharmacy industry participants, and quantifies differences among outpatient dispensing formats. Section 1.3, provides an integrated overview of industry trends and crucial topics, with links to relevant sections within the full report.

- **Chapter 2: Pharmacy Industry Market Structure** (page 16) analyzes the industry’s prescription and revenue growth trends. It identifies the biggest pharmacies based on prescription revenues. It then analyzes recent market share trends for each dispensing format and the major national companies. This chapter also updates our analysis of retail clinics and pharmacist-provided clinical services, including medication therapy management services.

- **Chapter 3: Specialty Drugs and Specialty Pharmacies** (page 41) provides a comprehensive overview of specialty drugs and the pharmacies dispensing these medications. The chapter discusses the various definitions of specialty drugs and specialty pharmacies and summarizes the top specialty therapy classes and average prescription costs. We present our exclusive analysis of national market share for pharmacy-dispensed specialty drugs and provide a competitive analysis of the various organizations that compete to dispense specialty medications. Chapter 3 also reviews the channel strategies that pharmaceutical manufacturers use for specialty drugs.

Section II: Third-Party Payment and Pharmacy Benefits

- **Chapter 4: Payment and Spending for Prescription Drugs** (page 68) has been significantly expanded for the 2016 edition. We examine the primary payers for prescription drugs at retail, mail, and specialty pharmacies. Chapter 4 also analyzes recent changes in the payer mix and spending on traditional vs. specialty drugs. We also present the outlook for net prescription drug spending, gross spending changes on traditional and specialty drugs, and the future payer mix.

- **Chapter 5: Pharmacy Benefit Management** (page 82) identifies the PBM industry’s key participants, explains the services provided by PBMs to third-party payers, reviews the
crucial role of PBMs in pharmacy economics, describes the relationship between PBMs and pharmacies that participate in a PBM’s network, and reviews how Pharmacy Services Administration Organizations (PSAOs) intermediate between retail pharmacies and PBMs. This year’s edition also includes new material on how payers compensate PBMs for benefit management services.

- **Chapter 6: Consumer Copayments and Coinsurance** (page 103) analyzes the benefit designs and plan structures that determine out-of-pocket spending for the major third-party payers: employer-sponsored health plans, Health Insurance Marketplace (HIM) plans, Medicare Part D, and Medicaid. We also explore the growth of plans with prescription deductibles and manufacturers’ copay offset programs.

- **Chapter 7: Narrow Pharmacy Networks** (page 115), which is new for the 2016 edition, analyzes the structure, utilization, and economics of narrow network models. We explain the use and economics of narrow networks for retail pharmacies in commercial health plans and Medicare Part D. We also review the use of mail pharmacies as preferred and restricted options. This chapter explores how narrow networks affect pharmacy profits and describes the development of new performance-based narrow networks. We also evaluate payer-defined networks for specialty drug dispensing.

**Section III: Drug Channel Economics**

- **Chapter 8: Prescription Reimbursement by Third-Party Payers** (page 131) explains the latest formulas and methodologies for computing a pharmacy’s revenue from brand-name, generic, and specialty prescriptions. This chapter compares and contrasts traditional list price methods with acquisition cost reimbursement approaches. We also review the economics of mail vs. retail pharmacies for payers and consumers. This chapter concludes by illustrating how prescription reimbursement, formulary rebates, and consumer copayments affect a plan sponsor’s net costs for a prescription.

- **Chapter 9: Relationships with Pharmaceutical Wholesalers** (page 152) explores the interactions of pharmacies with their primary suppliers of drugs. It explains wholesalers’ channel roles and services, identifies the largest wholesale suppliers, and analyzes wholesalers’ role for specialty drugs and specialty pharmacies. This chapter also analyzes wholesalers’ changing relationships with retail chains.

- **Chapter 10: Pharmacy and Prescription Profitability** (page 178) unites the reimbursement and cost discussion from Chapters 8 and 9 by presenting the latest data on pharmacy and prescription profitability. This section documents overall drugstore profitability, pharmacy margins for prescriptions, profit differences between brand and generic prescriptions, and PBMs’ per-prescription profits from network and mail pharmacies. Finally, we consider pharmacy profits in the 340B drug pricing program.
Using the 2016 Report

The chapters are self-contained and do not need to be read in order. We include extensive internal references to help you navigate the entire document and customize it to your specific needs. There are also nearly 400 endnotes, most of which have hyperlinks to original source materials.

Please note that highlighted internal references are clickable hyperlinks in the PDF document. After clicking a link, use the following shortcuts to return to your previous location in the document:

- Windows: ALT+Left Arrow
- Mac: Command+Left Arrow

To search the entire PDF document for every occurrence of a word or phrase, use the following keyboard shortcuts:

- Windows: Shift+CTRL+F
- Mac: Shift+Command+F

As always, I welcome your comments and feedback. Please contact me if you have any questions or comments about The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies.

Adam J. Fein
January 2016

P.S. You can find post-publication errata here:
The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies

CONTENTS

SECTION I: THE U.S. PHARMACY INDUSTRY ................................................................. 1

Chapter 1: Industry Overview ....................................................................................... 2

1.1. Defining the Practice of Pharmacy ...................................................................... 2

1.1.1. The Products That Pharmacies Dispense ......................................................... 3

1.1.2. Top Traditional Therapy Classes and Average Prescription Costs .................. 4

1.1.3. Pharmacies and the Drug Supply Chain Security Act ....................................... 5

1.2. Pharmacy Industry Participants .......................................................................... 6

1.2.1. Outpatient Pharmacy Dispensing Formats ...................................................... 6

1.2.2. Differences Among Outpatient Dispensing Formats ....................................... 8

1.2.3. Pharmacist Employment and Salaries ............................................................. 11

1.3. Pharmacy Industry Trends and Report Overview ............................................... 13

Chapter 2: Pharmacy Industry Market Structure ......................................................... 16

2.1. Industry Trends .................................................................................................... 16

2.1.1. Total and 30-Day Equivalent Prescriptions ..................................................... 16

2.1.2. Pharmacy Industry Revenues ........................................................................ 19

2.2. National Market Share by Company .................................................................... 20

2.3. Trends by Dispensing Format .............................................................................. 21

2.3.1. Revenues, Prescriptions, and Number of Pharmacies: 2010 to 2015 Trends ...... 21

2.3.2. Market Changes in 2015 ................................................................................ 23

2.3.3. National Retail Chains .................................................................................... 25

2.3.4. Regional Drugstore Chains ............................................................................ 28

2.3.5. Independent Pharmacies ................................................................................ 29

2.3.6. Mail Pharmacies ............................................................................................ 31

2.4. Compensation for Healthcare Services .............................................................. 34

2.4.1. Retail Clinics .................................................................................................. 35

2.4.2. Clinical Services and Medication Therapy Management (MTM) ..................... 37

2.4.3. Immunization .................................................................................................. 40

Chapter 3: Specialty Drugs and Specialty Pharmacies ............................................... 41

3.1. Specialty Drugs .................................................................................................... 41
3.1.1. Common Characteristics of Specialty Drugs .......................................................... 41
3.1.2. How Payers Define Specialty Drugs ...................................................................... 42
3.1.3. Top Specialty Therapy Classes and Average Prescription Costs .......................... 44
3.1.4. Specialty’s Share of Pharmacy Benefit Spending .................................................. 45
3.2. Specialty Pharmacies ................................................................................................. 46
3.2.1. Defining Specialty Pharmacy .................................................................................. 46
3.2.2. Clinical and Data Services ...................................................................................... 47
3.2.3. Accreditation ........................................................................................................... 49
3.2.4. Number of Specialty Pharmacies ........................................................................... 49
3.3. Specialty Market Participants ...................................................................................... 51
3.3.1. Overview ................................................................................................................ 51
3.3.2. Pharmacy Benefit Managers ................................................................................ 52
3.3.3. Independent Specialty Pharmacies ........................................................................ 52
3.3.4. Retail Chains .......................................................................................................... 54
3.3.5. Hospitals and Health Systems .............................................................................. 56
3.3.6. Physician Practices ................................................................................................. 57
3.3.7. Wholesalers ............................................................................................................ 58
3.4. National Market Share for Specialty Pharmaceuticals ............................................... 59
3.5. Mergers and Acquisitions Among Specialty Pharmacies ........................................... 60
3.6. Manufacturer Channel Strategies for Specialty Drugs .............................................. 62
3.6.1. Manufacturer-Defined Dispensing Networks ......................................................... 62
3.6.2. Specialty Hub Services .......................................................................................... 64
3.7. The Outlook for Pharmacy-Dispensed Biosimilars .................................................... 65
SECTION II: THIRD-PARTY PAYMENT AND PHARMACY BENEFITS ........................................ 67
Chapter 4: Payment and Spending for Prescription Drugs ................................................. 68
4.1. Prescription Drugs and U.S. Healthcare Spending ..................................................... 68
4.2. Recent Payer and Spending Trends .......................................................................... 69
4.2.1. Payment for Prescription Drugs in 2014 ............................................................... 69
4.2.2. Net Drug Spending in 2014: Payer Trends ............................................................ 71
4.2.3. Gross Drug Spending in 2014: Traditional vs. Specialty ....................................... 73
4.3. The Drug Spending Outlook ....................................................................................... 75
7.1.2. The Appeal of Narrow Networks .......................................................... 117
7.2. Retail Pharmacy Networks ..................................................................... 119
  7.2.1. Preferred Retail Networks in Medicare Part D .................................. 119
  7.2.2. Narrow Retail Networks in Commercial Health Plans ...................... 122
  7.2.3. Narrow Mail Networks in Commercial and Other Health Plans ........ 124
  7.2.4. Pharmacy Profits as the Source of Cost Savings in Narrow Retail Networks ......................................................................................... 125
7.3. The Emergence of Performance-Based Pharmacy Networks ................. 126
7.4. Payer-Defined Specialty Dispensing Networks ....................................... 127

SECTION III: DRUG CHANNEL ECONOMICS .................................................. 130

Chapter 8: Prescription Reimbursement by Third-Party Payers ..................... 131
  8.1. The Basics of Prescription Reimbursement .......................................... 131
  8.1.1. Estimated Acquisition Cost (EAC) ...................................................... 132
  8.1.2. Dispensing Fees ................................................................................ 133
  8.1.3. Service and Data Fees ...................................................................... 134
  8.2. Reimbursement for Brand-Name and Specialty Prescriptions .............. 135
  8.2.1. Wholesale Acquisition Cost (WAC) and Average Wholesale Price (AWP) List Prices ............................................................ 135
  8.2.2. Why List Prices Are Used for Brand-Name Prescription Reimbursement .......................................................................................... 136
  8.2.3. Average AWP Discounts for Pharmacy Reimbursement .................. 137
  8.2.4. Retail vs. Mail Reimbursement Rates for Brand-Name Drugs .......... 138
  8.2.5. Why Mail Pharmacies Accept Lower Reimbursements .................... 140
  8.3. Reimbursement for Generic Prescriptions .......................................... 141
  8.3.1. Challenges for List-Price Benchmarks .............................................. 141
  8.3.2. Maximum Allowable Cost (MAC) Limits ........................................ 142
  8.3.3. Regulation and Laws Regarding MAC Limits ................................... 143
  8.3.4. Medicaid and Federal Upper Limits ............................................... 144
  8.4. Acquisition Cost Reimbursement ......................................................... 145
  8.4.1. The AAC and NADAC Benchmarks ................................................ 145
  8.4.2. Adoption of Acquisition Cost by State Medicaid Programs ............... 147
  8.5. Manufacturer Sales Price Methods ..................................................... 148
  8.5.1. Medicaid and AMP-Based Federal Upper Limits ....................... 148
  8.5.2. Average Sales Price (ASP) ............................................................... 149
8.6. How Prescription Reimbursement, Formulary Rebates, Consumer Copayments, and PBM Expenses Affect Plan Sponsor Costs ......................................................................................................................... 150

Chapter 9: Relationships with Pharmaceutical Wholesalers ................................................................................................. 152

9.1. Wholesale Suppliers to Pharmacies ......................................................................................................................................... 152

9.1.1. Largest Companies ................................................................................................................................................................. 152

9.1.2. Full-Line Wholesalers ................................................................................................................................................................. 153

9.1.3. Specialty Distributors ................................................................................................................................................................. 154

9.2. Wholesalers’ Channel Role for Pharmacies .............................................................................................................................. 155

9.2.1. Physical Distribution .............................................................................................................................................................. 155

9.2.2. Financial Intermediation .......................................................................................................................................................... 156

9.2.3. Cost-Minus Pricing of Brand-Name Drugs to Pharmacies ........................................................................................................ 157

9.2.4. Influence on Pharmacy Reimbursement .............................................................................................................................. 159

9.3. Relationships with Independent Drugstores ............................................................................................................................ 159

9.3.1. Wholesaler Services for Independent Pharmacies ..................................................................................................................... 160

9.3.2. Wholesaler Relationships with Pharmacy Buying Groups ....................................................................................................... 163

9.3.3. Wholesaler Generic Programs for Retail Pharmacies ............................................................................................................ 164

9.4. Large Retail Chains and Mail Pharmacies ............................................................................................................................ 165

9.4.1. Wholesale Suppliers to Largest U.S. Pharmacies .......................................................................................................................... 165

9.4.2. Changing Distribution Relationships Between Wholesalers and Retail Chains ....................................................................... 166

9.4.3. Changing Generic Sourcing Relationships Between Wholesalers and Large Pharmacies .......................................................... 168

9.5. Wholesaler Relationships with the Three Largest Drugstore Chains .................................................................................... 170

9.5.1. Walgreens-AmerisourceBergen Relationship ............................................................................................................................... 170

9.5.2. CVS Health-Cardinal Health Relationship .............................................................................................................................. 172

9.5.3. Rite Aid-McKesson Relationship .............................................................................................................................................. 173

9.6. Wholesalers’ Role in Pharmacy-Dispensed Specialty Drug Distribution .................................................................................. 174

9.6.1. Specialty Products with Limited Pharmacy Networks ............................................................................................................. 175

9.6.2. Specialty Products in Open Distribution ................................................................................................................................ 176

Chapter 10: Pharmacy and Prescription Profitability .................................................................................................................. 178

10.1. Overall Drugstore Gross Margins ........................................................................................................................................ 178

10.1.1. Industry Averages ................................................................................................................................................................. 178

10.1.2. Large Chain Drugstores ..................................................................................................................................................... 180
10.2. Pharmacy Per-Prescription Profits ................................................................. 180
  10.2.1. Sources of Per-Prescription Profits ....................................................... 180
  10.2.2. Average Prescription Gross Margins...................................................... 182
  10.2.3. PBM Per-Prescription Profits from Network and Mail Pharmacies ............. 184
  10.2.4. Pharmacy Profits with Acquisition Cost-Based Reimbursement .................. 185

10.3. Profitability for Generic Prescriptions ................................................................ 186
  10.3.1. Lifecycle Profits for Generic Drugs ......................................................... 186
  10.3.2. Retail Generic Drug Discount Programs................................................... 190
  10.3.3. The Impact of Generic Price Inflation ...................................................... 192

10.4. Pharmacy Profits from the 340B Drug Pricing Program .................................... 193
  10.4.1. Overview of the 340B Program ............................................................... 193
  10.4.2. The Role and Identity of 340B Contract Pharmacies .............................. 194
  10.4.3. Flow of Funds with a Contract Pharmacy ............................................... 195
  10.4.4. Pharmacy and Covered Entity Profits from 340B Prescriptions .................. 196

Acronyms and Abbreviations ....................................................................................... 198

Endnotes ..................................................................................................................... 199
LIST OF EXHIBITS

Exhibit 1: Top 10 Traditional Therapy Categories and Average Prescription Cost, 2014 .........................................................4
Exhibit 2: Timeline of DSCSA Requirements for Pharmacies (Dispensers) ..........................................................................................5
Exhibit 3: Average Annual Number of Prescriptions per Pharmacy, by Retail Dispensing Format, 2015 ...........................................9
Exhibit 4: Average Annual Prescription Revenue per Pharmacy Outlet, 2015 ......................................................................................9
Exhibit 5: Average Wait Time for Prescription Pickup and Pharmacist Consultation, by Dispensing Format, 2014 ..........................10
Exhibit 6: Customer Satisfaction with Pharmacies, by Dispensing Format, 2015 .............................................................................10
Exhibit 7: Top Three Reasons for Pharmacy Selection, by Dispensing Format, 2014 .................................................................11
Exhibit 8: Pharmacist Employment and Salary, by Dispensing Format, 2014 ................................................................................12
Exhibit 9: Pharmacist Employment, by Dispensing Format, 2014 vs. 2024 ................................................................................13
Exhibit 10: Total U.S. Pharmacy Industry Revenues, Prescriptions, and Locations, by Dispensing Format, 2015 ........................16
Exhibit 11: Outpatient Prescriptions, Annual Total and Growth, 2010-2015 .............................................................17
Exhibit 12: 30-Day Equivalent Outpatient Prescriptions, Annual Total and Growth, 2010-2015 ....................................................17
Exhibit 13: 90-Day Prescriptions as a Percentage of Total Prescriptions, by Dispensing Format, 2010 vs. 2015 ..................18
Exhibit 14: Pharmacy Industry Revenues, Annual Total and Growth, 2010-2015 .................................................................19
Exhibit 15: Largest 15 U.S. Pharmacies Ranked by Total Prescription Revenues, 2015 ............................................................20
Exhibit 16: Share of Revenue Growth, by Dispensing Pharmacy Format, 2010 vs. 2015 .................................................................21
Exhibit 17: Total Change in 30-Day Equivalent Prescriptions Dispensed, by Pharmacy Format, 2010-2015 .............................22
Exhibit 18: Number of Pharmacies, by Dispensing Format, 2010 vs. 2015 ................................................................................23
Exhibit 19: Number of 30-Day Equivalent Prescriptions, by Dispensing Format, 2014 vs. 2015 ....................................................23
Exhibit 20: Prescription Revenues, by Dispensing Format, 2014 vs. 2015 .................................................................24
Exhibit 21: Year-Over-Year Change in Same-Store Prescription Count, 2012-2015 .................................................................25
Exhibit 22: Top 10 Regional Chain Drugstores, by Total Prescription Revenues, 2014 ..............................................................28
Exhibit 23: Number of Independent Pharmacies, 1990-2015 .................................................................................................30
Exhibit 24: Mail Prescriptions, Annual Total and Growth, 2003-2015 ........................................................................................31
Exhibit 25: Share of Mail Pharmacy Revenues, by Company, 2015 ...........................................................................................34
Exhibit 26: Number of U.S. Retail Clinics, 2004-2017 ..................................................................................................................35
Exhibit 27: Location of Retail Clinics, by Chain, 2015 ..................................................................................................................36
Exhibit 28: Providers of Medication Therapy Management Services, Medicare Part D, 2015 .........................................................39
Exhibit 29: Adult Influenza Vaccination, by Place of Vaccination, 2012-13 vs. 2015-16 Seasons ....................................................40
Exhibit 30: Factors Determining Health Plan Classification as Specialty Therapy, 2011 vs. 2014 ..............................................43
Exhibit 31: Top 10 Specialty Therapy Categories and Average Prescription Cost, 2014 ..............................................................44
Exhibit 32: Specialty Drug Approvals, 2005 to 2015 ..................................................................................................................45
Exhibit 33: Specialty Drugs as a Percentage of Pharmacy Benefit Spending, by PBM, 2011-2014 .................................................46
Exhibit 34: Number of Pharmacy Locations with Specialty Pharmacy Accreditation, URAC vs. ACHC, January 2016 50
Exhibit 35: Locations with URAC Specialty Pharmacy Accreditation, 2008-2016 ..........................................................50
The 2016 Economic Report on Retail, Mail, and Specialty Pharmacies

Exhibit 71: Distribution of Cost-Sharing Formulas for Prescription Drug Benefits in Employer-Sponsored Plans, 2005 vs. 2015 .................................................................................................................. 104
Exhibit 72: Average Copayments by Prescription Drug Tier, Employer-Sponsored Plans, 2005 vs. 2015 .......................................................... 104
Exhibit 73: Cost-Sharing Arrangements for Prescription Drug Benefits in Employer-Sponsored Plans, 2015 .................. 105
Exhibit 74: Average Copayments by Prescription Drug Tier, Bronze vs. Platinum Health Insurance Marketplace Plans, 2015 .................................................................................................................. 106
Exhibit 75: Type of Cost-Sharing for Prescription Drug Benefits, Health Insurance Marketplace Plans, Platinum Plans, 2016 .................................................................................................................. 106
Exhibit 76: Type of Cost-Sharing for Prescription Drug Benefits, Health Insurance Marketplace Plans, Bronze Plans, 2016 .................................................................................................................. 107
Exhibit 77: Standard Medicare Prescription Drug Benefit, 2016 .................................................................................................................. 108
Exhibit 78: Median Copayments by Prescription Drug Tier, Medicare Part D Plans, 2015 .......................................................... 109
Exhibit 79: Type of Cost-Sharing for Prescription Drug Benefits, Medicare Part D Prescription Drug Plans, 2015 .......................................................... 109
Exhibit 80: Percentage of Employer-Sponsored Plans with Pharmacy Benefit Deductibles, 2012 to 2015 .................. 111
Exhibit 81: Percentage of Health Insurance Marketplace Plans with Separate Prescription Drug Deductible, 2016 .................................................................................................................. 112
Exhibit 82: Sources of Free Trial Vouchers, Coupons, and Copay Cards, 2014 .................................................................................................................. 113
Exhibit 83: Summary of Pharmacy Benefit Network Design Options .................................................................................................................. 116
Exhibit 84: Medicare Part D PDPs with Preferred Pharmacy Networks, 2011-2016 .................................................................................................................. 119
Exhibit 85: Participation as Preferred Cost Sharing Pharmacies in Selected Medicare Part D PDPs, Retail Chain and Independent Pharmacies, 2016 .................................................................................................................. 121
Exhibit 86: Retail Pharmacy Network Design in Employer-Sponsored Plans, 2015 .................................................................................................................. 122
Exhibit 87: CVS Health, Maintenance Choice Covered Lives and Caremark Retail Channel Share, 2009 to 2015 .......................................................... 123
Exhibit 88: Mail Pharmacy Network Design in Employer-Sponsored Plans, Maintenance Medications, 2015 .................................................................................................................. 124
Exhibit 89: DIR Fees for Medicare Part D Preferred Cost-Sharing Pharmacies, 2015 .................................................................................................................. 126
Exhibit 90: Share of Hepatitis C Virus (HCV) Drug Expenditures, by Dispensing Format, 2014 .................................................................................................................. 128
Exhibit 91: Payer-Mandated Usage of Specialty Pharmacies for Oncology Products, by Product Type, 2010-2014 .......................................................... 129
Exhibit 92: Payer Methodologies for Computing a Pharmacy’s Estimated Acquisition Cost (EAC) .................................................................................................................. 133
Exhibit 93: Average Dispensing Fee for Brand-Name Prescriptions at Retail Pharmacies, 1999 to 2015 .................................................................................................................. 133
Exhibit 94: Methodology Used to Compute Average Wholesale Price, by Publisher .................................................................................................................. 137
Exhibit 95: Reimbursement of Brand-Name Prescriptions, Percentage of Average Wholesale Price, by Dispensing Format, 2015 .................................................................................................................. 138
Exhibit 96: Reimbursement of Specialty Drug Prescriptions at Specialty Pharmacies, Percentage of Average Wholesale Price, 2004 to 2014 .................................................................................................................. 138
Exhibit 97: Percentage of AWP Billed to Employers for Brand-Name Prescriptions, Retail vs. Mail, 1999 to 2015 .................................................................................................................. 139
Exhibit 98: Generic Drugs, Comparison of Per-Unit Pricing Metrics and Pharmacy Acquisition Cost, Medicaid .................................................................................................................. 142
Exhibit 99: Reimbursement of Generic Prescriptions, Percentage of Average Wholesale Price and Copayment, by Dispensing Format, 2015 .................................................................................................................. 142
Exhibit 100: Acquisition Cost Methodologies for Pharmacy Reimbursement Used by State Medicaid Programs, 2015 ................................................................. 147
Exhibit 101: Example of Brand-Name Prescription Economics for a Third-Party Payer ................................................................. 150
Exhibit 102: U.S. Drug Distribution and Related Revenues at Big Three Wholesalers, 2015 ................................................................. 152
Exhibit 103: Full-Line Wholesaler Sales, by Type of Customer, 2014 ................................................................. 154
Exhibit 104: Full-Line Wholesalers, Inventory Levels vs. Product Sales, by Product Type, 2014 ................................................................. 154
Exhibit 105: Determination of a Pharmacy’s Brand-Name Drug Acquisition Cost from a Wholesaler ................................................................. 157
Exhibit 106: Estimated Market Share with Independent Pharmacies, by Wholesaler, 2014 ................................................................. 160
Exhibit 107: U.S. Pharmacy Franchise and Marketing Programs of Large Drug Wholesalers, 2014 ................................................................. 161
Exhibit 108: Pharmacy Buying Groups and Primary/Preferred Wholesaler Relationship, 2015 ................................................................. 163
Exhibit 109: Largest U.S. Pharmacies and Their Primary Wholesale Suppliers ................................................................. 165
Exhibit 110: Full-Line Wholesaler Sales to Retail Chain Warehouses, 2008 to 2014 ................................................................. 167
Exhibit 111: Share of U.S. Generic Purchasing Volume, by Organization, 2015 ................................................................. 169
Exhibit 113: Rite Aid, Total Inventories and Days Sales in Inventory, 2013 to 2015 ................................................................. 174
Exhibit 114: Alternative Channels to Specialty Pharmacies in Limited Networks ................................................................. 176
Exhibit 115: Overall Gross Margins for Chain and Independent Drugstores, 1993-2013 ................................................................. 179
Exhibit 116: Total Gross Profits for Chain and Independent Drugstores, 2003-2013 ................................................................. 179
Exhibit 117: Overall Gross Margins for Drugstores, by Company, 2014 ................................................................. 180
Exhibit 118: Example of Brand-Name Prescription Economics for a Pharmacy ................................................................. 181
Exhibit 119: Average Prescription Gross Margins at Independent Drugstores, 2006-2014 ................................................................. 182
Exhibit 120: Diplomat Pharmacy, Per-Prescription Revenues and Profits, 2011-2015 ................................................................. 183
Exhibit 121: Average Retail Pharmacy Gross Margin per Prescription, Brand-Name vs. Generic Drugs, 2012 ................................................................. 184
Exhibit 122: PBM Gross Margin per Equivalent Script, by Channel and Drug Type, 2015 ................................................................. 185
Exhibit 123: Lifecycle of Per-Prescription Gross Profits, Brand vs. Multisource Generic ................................................................. 187
Exhibit 124: Incremental Pharmacy Gross Profits from Newly Launched Generics, 2011-2016 ................................................................. 188
Exhibit 125: Examples of Pharmacy Acquisition Cost, Brand-Name vs. Generic Drug, 2015 ................................................................. 189
Exhibit 126: Number of Products on Retail Generic Discount Lists, by Retail Chain, 2012 vs. 2015 ................................................................. 192
Exhibit 127: 340B Contract Pharmacy Locations, by Chain, 2015 ................................................................. 194
Exhibit 128: Flow of Funds and Product for 340B Contract Pharmacy Network ................................................................. 195
Exhibit 129: Hypothetical Profits for a 340B Entity From a Third-Party Prescription Dispensed by a 340B Contract Pharmacy ................................................................. 197